Registry for understanding the natural course of pustular psoriasis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational registry aims to describe the natural progression of different subtypes of pustular psoriasis (PP) over a five-year period. It builds on a previous European registry and involves multiple clinicians who will collect detailed clinical data, including biological samples and phenotypic descriptions. The study focuses on understanding the frequency and severity of disease flares and the impact of existing treatments on patients with PP. By gathering this information, the registry seeks to provide insights into the burden of the disease and improve patient management.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Written informed consent of the patient or legal proxy in the registry
* Diagnosis of PP confirmed by a dermatologist in the participant. The type of PP can be any one of PPP, GPP/Acute Generalized Exanthematous Pustulosis (AGEP), ACH or a mixed phenotype, according to the judgment of the investigator
* GPP: Primary, sterile, macroscopically visible epidermal pustules on non-acral Skin with or without systemic Inflammation; with or without plaque psoriasis; either relapsing (\>1 episode) or persistent (\>3 months)
* PPP: Primary, persistent (\>3 months), sterile, macroscopically visible epidermal pustules on palms and/or soles with or without plaque psoriasis
* ACH: Primary, persistent (\>3 months), sterile, macroscopically visible epidermal pustules affecting the nail apparatus with or without plaque psoriasis
* At the timepoint of inclusion, the participant must have had active pustulation with either white, yellow or brown pustules within six month before baseline. Active postulation at baseline is not mandatory for inclusion.
* Sufficient language skills (in the languages which the patient information and the consent form is available) for the informed consent to participate
* Patients of all ancestries and skin pigment type can be included
* Direct non-affected adult (\>18 years old) relatives of the participant (up to two, namely mother, father, sibling) with the purpose to provide DNA for family trio sequencing analysis. The patient is not excluded from the study if no relatives are included.

Exclusion Criteria:

* Any medical or psychological condition in the treating physician's opinion which may prevent the patient in registry participation for the next 5 years
* Lack of informed consent for registry participation

Where it's running

• Klinikum der Universität München
  München, Germany Recruiting
• Fondazione Policlinico Universitario "Agostino Gemelli" IRCCS
  Rome, Italy Recruiting
• Universitário do Porto
  Porto, Portugal Recruiting
• National Skin Centre
  Singapore, Singapore Recruiting
• Dermatology, University Hospital Basel
  Basel, Switzerland Recruiting
• University Hospital Zürich
  Zurich, Switzerland Recruiting

Study contacts

• Principal investigator: Alexander Navarini, Prof. Dr. med. Dr. sc. nat. — Dermatologie, Universitätsspital Basel
• Study coordinator: Alexander Navarini, Prof. Dr. med. Dr. sc. nat.
• Email: alexander.navarini@usb.ch
• Phone: +41 61 328 60 80

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Topical PROXERA PSOMED 20 or 40 for psoriasis in adults

  This study tests whether applying PROXERA PSOMED 20 or 40 to a psoriasis-affected area helps more than the untreated area on the same person.

  Recruiting ICIM International S.r.l. · Chieti, Italia · NCT07545902

• Evaluating HB0034 for treating severe flares of generalized pustular psoriasis

  This study is testing if a new treatment called HB0034 can help people with severe flare-ups of generalized pustular psoriasis feel better.

  Recruiting at 2 sites Phase 2 Shanghai Huaota Biopharmaceutical Co., Ltd. · Beijing and 1 other locations · NCT06231381

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.